Patents by Inventor Mari Yokoyama

Mari Yokoyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20200206330
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • Partner of SLD five 1 (PSF1)-derived peptide
    Patent number: 10617750
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: April 14, 2020
    Assignee: Vasculead Inc.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20180169203
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Applicant: Vasculead Inc.
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • Partner of SLD five 1 (PSF1)-derived peptide
    Patent number: 9919039
    Abstract: A Partner of Sld Five 1 (PSF1)-derived peptide that can induce a Cytotoxic T-Cell (CTL) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 20, 2018
    Assignee: VASCULEAD INC.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • PARTNER OF SLD FIVE 1 (PSF1)-DERIVED PEPTIDE
    Publication number: 20170173133
    Abstract: Embodiments of the present invention provide a PSF1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides a PSF1-derived peptide which can induce a CTL and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the embodiments of the present invention.
    Type: Application
    Filed: January 23, 2017
    Publication date: June 22, 2017
    Applicants: GeneStem Co., Ltd., Osaka Urban Industry Promotion Center
    Inventors: Hidekazu TANAKA, Motofumi IGUCHI, Mari YOKOYAMA
  • PSF1-derived peptide
    Patent number: 9683016
    Abstract: PSF 1-derived peptides and pharmaceutical compositions of the peptides are described for immunotherapy of cancer patients. The peptides and pharmaceutical compositions containing these peptides induce a CTL response for treating or preventing cancer.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 20, 2017
    Assignees: GENESTEM CO., LTD., OSAKA URBAN INDUSTRY PROMOTION CENTER
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • PSF1-DERIVED PEPTIDE
    Publication number: 20150218216
    Abstract: The purpose of the present invention is to provide a PSF1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides: a PSF1-derived peptide which can induce a CTL; and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention.
    Type: Application
    Filed: August 29, 2013
    Publication date: August 6, 2015
    Applicant: GeneStem Co., Ltd.
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • POWDER, METHOD OF PRODUCING POWDER AND ADSORPTION APPARATUS
    Publication number: 20120238444
    Abstract: The present invention is powder constituted from particles of a compound represented by the following general formula (1), (Ca1-aMa)10(PO4)6((OH)1-bFb)2 (1), where in the formula M is a divalent metal element, and the following relations are satisfied: 0<a?1 and 0?b?1. Each of the particles has a surface, a central part, a specific distance part in which a distance from the surface toward the central part is 15 nm, and an area part from the specific distance part to the central part. An amount of the divalent metal element is 3.2 wt % or more in the area part.
    Type: Application
    Filed: October 4, 2010
    Publication date: September 20, 2012
    Applicant: HOYA CORPORATION
    Inventors: Yukiko Murakami, Mari Yokoyama, Shintaro Kobayashi